MacroGenics Accounts Payable vs Total Liab Analysis

MGNX Stock  USD 3.59  0.05  1.37%   
MacroGenics financial indicator trend analysis is infinitely more than just investigating MacroGenics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MacroGenics is a good investment. Please check the relationship between MacroGenics Accounts Payable and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MacroGenics Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have weak relationship.
The correlation between MacroGenics' Accounts Payable and Total Liab is 0.33. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of MacroGenics, assuming nothing else is changed. The correlation between historical values of MacroGenics' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of MacroGenics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., MacroGenics' Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.33
Relationship DirectionPositive 
Relationship StrengthVery Weak

Accounts Payable

An accounting item on the balance sheet that represents MacroGenics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of MacroGenics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.
Most indicators from MacroGenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.At this time, MacroGenics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 275.27 in 2024, whereas Selling General Administrative is likely to drop slightly above 37 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses275.8M266.0M217.2M181.0M
Cost Of Revenue2.7M7.4M8.2M7.8M

MacroGenics fundamental ratios Correlations

0.310.380.97-0.240.78-0.33-0.58-0.53-0.130.740.80.410.220.950.390.810.740.080.520.760.210.520.99-0.280.84
0.310.30.240.150.320.010.01-0.280.20.070.330.130.080.250.210.160.50.230.20.30.310.250.29-1.00.16
0.380.30.20.010.670.24-0.02-0.670.640.170.670.380.610.160.450.540.670.290.680.660.70.680.27-0.280.54
0.970.240.2-0.390.62-0.5-0.66-0.33-0.220.780.680.430.190.980.230.680.56-0.120.450.59-0.040.370.98-0.210.71
-0.240.150.01-0.390.10.640.36-0.33-0.14-0.23-0.12-0.73-0.46-0.310.37-0.020.090.84-0.430.060.560.24-0.25-0.16-0.05
0.780.320.670.620.10.15-0.35-0.72-0.040.540.950.310.140.560.750.820.840.410.460.840.650.580.68-0.290.83
-0.330.010.24-0.50.640.150.45-0.360.23-0.380.01-0.46-0.02-0.540.670.040.180.58-0.050.180.62-0.05-0.39-0.010.04
-0.580.01-0.02-0.660.36-0.350.45-0.20.43-0.93-0.31-0.180.04-0.63-0.12-0.22-0.050.42-0.05-0.080.270.06-0.61-0.02-0.25
-0.53-0.28-0.67-0.33-0.33-0.72-0.36-0.2-0.3-0.12-0.72-0.22-0.34-0.31-0.62-0.83-0.89-0.75-0.63-0.91-0.81-0.82-0.440.25-0.83
-0.130.20.64-0.22-0.14-0.040.230.43-0.3-0.380.060.310.69-0.22-0.040.020.220.040.580.20.330.28-0.17-0.20.02
0.740.070.170.78-0.230.54-0.38-0.93-0.12-0.380.510.260.00.740.270.450.29-0.140.220.32-0.080.230.76-0.050.48
0.80.330.670.68-0.120.950.01-0.31-0.720.060.510.560.250.590.660.830.850.280.620.850.540.570.7-0.30.85
0.410.130.380.43-0.730.31-0.46-0.18-0.220.310.260.560.430.32-0.050.350.35-0.310.70.36-0.040.220.34-0.110.38
0.220.080.610.19-0.460.14-0.020.04-0.340.690.00.250.430.16-0.020.330.38-0.210.770.40.140.380.2-0.070.35
0.950.250.160.98-0.310.56-0.54-0.63-0.31-0.220.740.590.320.160.130.660.54-0.070.380.56-0.030.420.98-0.230.68
0.390.210.450.230.370.750.67-0.12-0.62-0.040.270.66-0.05-0.020.130.550.620.520.280.630.660.20.3-0.190.58
0.810.160.540.68-0.020.820.04-0.22-0.830.020.450.830.350.330.660.550.910.40.640.960.590.670.76-0.130.99
0.740.50.670.560.090.840.18-0.05-0.890.220.290.850.350.380.540.620.910.510.680.970.730.690.66-0.480.91
0.080.230.29-0.120.840.410.580.42-0.750.04-0.140.28-0.31-0.21-0.070.520.40.510.020.490.780.590.03-0.230.38
0.520.20.680.45-0.430.46-0.05-0.05-0.630.580.220.620.70.770.380.280.640.680.020.710.320.520.46-0.180.67
0.760.30.660.590.060.840.18-0.08-0.910.20.320.850.360.40.560.630.960.970.490.710.720.70.69-0.280.96
0.210.310.7-0.040.560.650.620.27-0.810.33-0.080.54-0.040.14-0.030.660.590.730.780.320.720.590.11-0.30.56
0.520.250.680.370.240.58-0.050.06-0.820.280.230.570.220.380.420.20.670.690.590.520.70.590.47-0.220.66
0.990.290.270.98-0.250.68-0.39-0.61-0.44-0.170.760.70.340.20.980.30.760.660.030.460.690.110.47-0.260.78
-0.28-1.0-0.28-0.21-0.16-0.29-0.01-0.020.25-0.2-0.05-0.3-0.11-0.07-0.23-0.19-0.13-0.48-0.23-0.18-0.28-0.3-0.22-0.26-0.13
0.840.160.540.71-0.050.830.04-0.25-0.830.020.480.850.380.350.680.580.990.910.380.670.960.560.660.78-0.13
Click cells to compare fundamentals

MacroGenics Account Relationship Matchups

MacroGenics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets312.5M378.7M335.2M280.5M298.4M287.5M
Other Current Liab27.1M26.2M24.4M19.5M24.2M25.5M
Total Current Liabilities45.2M50.7M74.6M48.6M56.1M47.8M
Total Stockholder Equity230.6M295.9M239.6M142.0M152.6M199.6M
Other Liab9.2M6.9M258K59.7M53.8M56.5M
Property Plant And Equipment Net48.2M42.2M37.7M56.9M45.7M32.9M
Current Deferred Revenue10.7M11.4M20.6M69.5M21.7M22.3M
Net Debt(95.9M)(151.9M)(98.0M)(74.1M)(67.0M)(70.3M)
Retained Earnings(642.1M)(771.8M)(973.9M)(1.1B)(1.1B)(1.0B)
Accounts Payable4.3M8.0M15.5M4.9M6.4M6.1M
Cash126.5M181.1M123.5M108.9M101.0M146.4M
Non Current Assets Total72.7M66.1M55.7M58.3M47.1M40.8M
Non Currrent Assets Other24.5M23.9M18.0M(7.7M)1.4M1.3M
Other Assets4.3M23.9M335.2M1.4M1.00.95
Cash And Short Term Investments215.8M272.5M243.6M154.3M229.8M224.7M
Net Receivables12.7M23.1M10.4M56.2M10.4M14.4M
Common Stock Total Equity490K562K613K617K709.6K396.0K
Common Stock Shares Outstanding48.1M52.4M59.9M61.4M61.9M42.1M
Liabilities And Stockholders Equity312.5M378.7M335.2M280.5M298.4M287.5M
Non Current Liabilities Total36.7M32.2M21.0M89.8M89.7M94.2M
Other Current Assets11.3M34.0M42.3M10.2M9.9M11.0M
Other Stockholder Equity872.2M1.1B1.2B1.2B1.3B774.0M
Total Liab81.9M82.9M95.6M138.5M145.8M87.9M
Property Plant And Equipment Gross48.2M42.2M110.5M29.6M134.1M140.8M
Total Current Assets239.8M312.6M279.6M222.2M251.3M246.7M
Accumulated Other Comprehensive Income(61K)(3K)16K(7K)(6K)(6.3K)
Short Term Debt3.0M8.0M9.4M9.5M3.8M3.6M
Common Stock490K562K613K617K621K418.1K
Property Plant Equipment68.4M42.2M37.7M29.6M34.0M30.8M
Net Tangible Assets230.6M295.9M239.6M142.0M163.3M245.6M
Short Term Investments89.3M91.4M120.1M45.5M128.8M91.7M
Capital Surpluse872.2M1.1B1.2B1.2B1.4B817.2M
Deferred Long Term Liab24.9M29.3M6.9M59.5M68.4M71.8M
Net Invested Capital230.6M295.9M239.6M142.0M152.6M183.2M
Net Working Capital194.6M261.9M205.0M173.6M195.2M172.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.